PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.07%
Revenue growth under 50% of CSIQ's 245.43%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-8.12%
Negative gross profit growth while CSIQ is at 614.74%. Joel Greenblatt would examine cost competitiveness or demand decline.
-285.53%
Negative EBIT growth while CSIQ is at 29.88%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-437.48%
Negative operating income growth while CSIQ is at 29.88%. Joel Greenblatt would press for urgent turnaround measures.
-531.05%
Negative net income growth while CSIQ stands at 25.51%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-455.50%
Negative EPS growth while CSIQ is at 21.43%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-455.50%
Negative diluted EPS growth while CSIQ is at 21.43%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.89%
Share count expansion well above CSIQ's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-5.06%
Reduced diluted shares while CSIQ is at 0.02%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
152.45%
OCF growth of 152.45% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
35.56%
FCF growth of 35.56% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
148.43%
10Y revenue/share CAGR under 50% of CSIQ's 2394.55%. Michael Burry would suspect a lasting competitive disadvantage.
148.43%
5Y revenue/share CAGR under 50% of CSIQ's 2394.55%. Michael Burry would suspect a significant competitive gap or product weakness.
148.43%
3Y revenue/share CAGR under 50% of CSIQ's 2394.55%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-93.69%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-93.69%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-93.69%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
80.22%
Positive 10Y CAGR while CSIQ is negative. John Neff might see a substantial advantage in bottom-line trajectory.
80.22%
Positive 5Y CAGR while CSIQ is negative. John Neff might view this as a strong mid-term relative advantage.
80.22%
Positive short-term CAGR while CSIQ is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.25%
AR growth is negative/stable vs. CSIQ's 95.14%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
37.61%
Inventory growth well above CSIQ's 23.02%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.15%
Asset growth well under 50% of CSIQ's 31.86%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
0.15%
Under 50% of CSIQ's 0.42%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
-3.92%
Our R&D shrinks while CSIQ invests at 9.68%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
16.71%
SG&A growth well above CSIQ's 22.23%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.